logo
Share SHARE
FONT-SIZE Plus   Neg

Genzyme, Veracyte Announce U.S. Availability Of Afirma Thyroid FNA Analysis

Genzyme, a Sanofi company (SNY: Quote), and Veracyte, Inc.,said Monday that the Afirma Thyroid FNA Analysis, an innovative approach for improved thyroid nodule diagnosis, is now available to patients across the United States.

The Afirma Thyroid FNA Analysis combines expert cytopathology assessment of thyroid nodule fine needle aspiration samples, with the Afirma Gene Expression Classifier, a novel genomic test, used to resolve inconclusive results and thus help patients whose nodules are actually benign avoid unnecessary surgery.

Two independent clinical studies to date have shown that the Afirma Gene Expression Classifier can reclassify patients with indeterminate thyroid FNA results as "benign" with the same degree of accuracy as a benign cytopathology diagnosis.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Mercedes-Benz Vans Friday said it would invest around $500 million to create a plant in Charleston, South Carolina to explore the future growth potential in North American Van market. After many years on the outside, tech giant Apple Inc. (AAPL) will finally be added to the Dow Jones Industrial Average, S&P Dow Jones Indices announced on Friday. Apple, the maker of the iPhone and iPad, will replace telecom giant AT&T Inc. (T) in the well-known stock market index. The Federal Reserve announced on Thursday that all of the thirty one largest banking institutions in the U.S. have passed the annual supervisory stress test, reflecting continued broad improvement in their capital positions since the financial crisis in 2008. These also included U.S. subsidiaries of large foreign banks.
comments powered by Disqus
RELATED NEWS
Trade SNY now with 
Follow RTT